↓ Skip to main content

Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis

Overview of attention for article published in Nature Communications, July 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
5 X users

Citations

dimensions_citation
93 Dimensions

Readers on

mendeley
97 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis
Published in
Nature Communications, July 2013
DOI 10.1038/ncomms3129
Pubmed ID
Authors

Kayoko Hosaka, Yunlong Yang, Takahiro Seki, Masaki Nakamura, Patrik Andersson, Pegah Rouhi, Xiaojuan Yang, Lasse Jensen, Sharon Lim, Ninghan Feng, Yuan Xue, Xuri Li, Ola Larsson, Toshio Ohhashi, Yihai Cao

Abstract

Anti-platelet-derived growth factor (PDGF) drugs are routinely used in front-line therapy for the treatment of various cancers, but the molecular mechanism underlying their dose-dependent impact on vascular remodelling remains poorly understood. Here we show that anti-PDGF drugs significantly inhibit tumour growth and metastasis in high PDGF-BB-producing tumours by preventing pericyte loss and vascular permeability, whereas they promote tumour cell dissemination and metastasis in PDGF-BB-low-producing or PDGF-BB-negative tumours by ablating pericytes from tumour vessels. We show that this opposing effect is due to PDGF-β signalling in pericytes. Persistent exposure of pericytes to PDGF-BB markedly downregulates PDGF-β and inactivation of the PDGF-β signalling decreases integrin α1β1 levels, which impairs pericyte adhesion to extracellular matrix components in blood vessels. Our data suggest that tumour PDGF-BB levels may serve as a biomarker for selection of tumour-bearing hosts for anti-PDGF therapy and unsupervised use of anti-PDGF drugs could potentially promote tumour invasion and metastasis.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ireland 1 1%
Sweden 1 1%
Canada 1 1%
Belgium 1 1%
Korea, Republic of 1 1%
Unknown 92 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 32 33%
Researcher 16 16%
Student > Master 8 8%
Student > Bachelor 7 7%
Student > Postgraduate 5 5%
Other 14 14%
Unknown 15 15%
Readers by discipline Count As %
Agricultural and Biological Sciences 23 24%
Biochemistry, Genetics and Molecular Biology 21 22%
Medicine and Dentistry 17 18%
Engineering 6 6%
Neuroscience 4 4%
Other 10 10%
Unknown 16 16%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2013.
All research outputs
#12,565,289
of 22,713,403 outputs
Outputs from Nature Communications
#37,138
of 46,755 outputs
Outputs of similar age
#95,467
of 194,174 outputs
Outputs of similar age from Nature Communications
#260
of 358 outputs
Altmetric has tracked 22,713,403 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 46,755 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 55.5. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,174 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 358 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.